PDQ-39 used to evaluate Health-Related Quality of Life in randomized controlled trial that uses DBS system to treat patients with Parkinson’s disease
19th April 2022
Patients were implanted bilaterally with Boston Scientific’s FDA-approved Vercise Genus DBS system. During long-term follow-up, quality of life was evaluated using the Parkinson’s Disease Questionnaire (PDQ-39).
“Follow-up results from the INTREPID randomized controlled trial (NCT01839396) showed that treatment with deep brain stimulation (DBS) capable of multiple independent current control (MICC) was safe and effective for treating patients with Parkinson disease (PD) for up to 4 years.”
In the trial, patients were implanted bilaterally with Boston Scientific’s FDA-approved Vercise Genus DBS system. During long-term follow-up, quality of life was evaluated using the Parkinson’s Disease Questionnaire (PDQ-39).
You can read more from the original article that was posted on Neurology Live, here.
The Parkinson’s Disease Questionnaire is a self completion PRO designed to address aspects of functioning and well-being for those affected by Parkinson’s disease. There are 39 questions in the long form Parkinson’s Disease Questionnaire, with 8 discrete scales:
- mobility (10 items)
- activities of daily living (6 items)
- emotional well-being (6 items)
- stigma (4 items)
- social support (3 items)
- cognitions (4 items)
- communication (3 items)
- bodily discomfort (3 items)
To find out more about the PDQ-39, please visit the Clinical Outcome Assessment page.
Press release sign up
